Fresh2 Group (Fresh2 Group) Dividend Payout Ratio : 0.00 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group Dividend Payout Ratio?

Fresh2 Group's dividend payout ratio for the months ended in Jun. 2023 was 0.00.

The historical rank and industry rank for Fresh2 Group's Dividend Payout Ratio or its related term are showing as below:

FRES's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-06), the Dividend Yield % of Fresh2 Group is 0.00%.

Fresh2 Group's Dividends per Share for the months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Fresh2 Group Dividend Payout Ratio Historical Data

The historical data trend for Fresh2 Group's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group Dividend Payout Ratio Chart

Fresh2 Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividend Payout Ratio

Get a 7-Day Free Trial

Fresh2 Group Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Dividend Payout Ratio	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Fresh2 Group's Dividend Payout Ratio

For the Biotechnology subindustry, Fresh2 Group's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh2 Group's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh2 Group's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Fresh2 Group's Dividend Payout Ratio falls into.

Fresh2 Group Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Fresh2 Group's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-6.054
	=	N/A

Fresh2 Group's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	0
	=	N/A

Fresh2 Group (NAS:FRES) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Fresh2 Group Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh2 Group (Fresh2 Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

0UC0:Germany

Address

650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108

Website

https://www.fresh2.co

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.